A Study to Assess Safety, Tolerability, and How Single and Multiple Injections or Infusions of ABBV-313 Affects the Body of Adult Participants
A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Single Ascending Doses and Multiple Doses of ABBV-313
The objective of this study is to assess the safety, tolerability, pharmacokinetics, and immunogenicity of single and multiple doses of ABBV-313 in healthy adult participants.
研究概览
研究类型
注册 (估计的)
阶段
- 阶段1
联系人和位置
学习联系方式
- 姓名:ABBVIE CALL CENTER
- 电话号码:844-663-3742
- 邮箱:abbvieclinicaltrials@abbvie.com
学习地点
-
-
California
-
Anaheim、California、美国、92801
- 招聘中
- CenExel Act- Anaheim Clinical Trials /ID# 285208
-
-
Illinois
-
Grayslake、Illinois、美国、60030
- 招聘中
- Acpru /Id# 283495
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- BMI is >= 18.0 to <= 29.9 kg/m2 after rounding to the tenths decimal at Screening. BMI is calculated as weight in kg divided by the square of height measured in meters.
- A condition of general good health, based upon the results of a medical history, physical examination, vital signs, laboratory profile and a 12-lead ECG.
Exclusion Criteria:
- History of any clinically significant sensitivity or allergy to any medication or food.
- History of any clinically significant illness/infection/major febrile illness, hospitalization, or any surgical procedure within 30 days prior to the first dose of study treatment.
- Participant has prior exposure to ABBV-313 within the past 300 days.
学习计划
研究是如何设计的?
设计细节
- 主要用途:基础科学
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:四人间
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Part 1, Group 1: ABBV-313 or Placebo
Participants will receive a single dose of ABBV-313 or Placebo |
Injection Injection Infusion Infusion |
|
实验性的:Part 1, Group 2: ABBV-313 or Placebo
Participants will receive a single dose of ABBV-313 or Placebo |
Injection Injection Infusion Infusion |
|
实验性的:Part 1, Group 3: ABBV-313 or Placebo
Participants will receive a single dose of ABBV-313 or Placebo |
Injection Injection Infusion Infusion |
|
实验性的:Part 1, Group 4: ABBV-313 or Placebo
Participants will receive a single dose of ABBV-313 or Placebo |
Injection Injection Infusion Infusion |
|
实验性的:Part 1, Group 5: ABBV-313 or Placebo
Participants will receive a single dose of ABBV-313 or Placebo |
Injection Injection Infusion Infusion |
|
实验性的:Part 1, Group 6: ABBV-313 or Placebo
Participants will receive a single dose of ABBV-313 or Placebo |
Injection Injection Infusion Infusion |
|
实验性的:Part 2, Group 7: ABBV-313 or Placebo
Participants will receive multiple doses of ABBV-313 or Placebo |
Injection Injection Infusion Infusion |
|
实验性的:Part 2, Group 8: ABBV-313 or Placebo
Participants will receive multiple doses of ABBV-313 or Placebo |
Injection Injection Infusion Infusion |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Number of Participants with Adverse Events (AEs)
大体时间:Up to Approximately Day 329
|
An AE is defined as any untoward medical occurrence in a patient or clinical investigation in which a participant is administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. |
Up to Approximately Day 329
|
|
Maximum Observed Plasma Concentration (Cmax) of ABBV-313
大体时间:Up to Approximately Day 329
|
Cmax of ABBV-313. |
Up to Approximately Day 329
|
|
Time to Cmax (Tmax) of ABBV-313
大体时间:Up to Approximately Day 329
|
Tmax of ABBV-313. |
Up to Approximately Day 329
|
|
Terminal Phase Elimination Rate Constant (Beta) of ABBV-313
大体时间:Up to Approximately Day 329
|
Beta of ABBV-313. |
Up to Approximately Day 329
|
|
Terminal Phase Elimination Half-Life (t1/2) of ABBV-313
大体时间:Up to Approximately Day 329
|
t1/2 of ABBV-313. |
Up to Approximately Day 329
|
|
Area Under the Plasma Concentration-Time Curve (AUC) From Time 0 to the Time of the Last Measurable Concentration (AUCt) of ABBV-313
大体时间:Up to Approximately Day 329
|
AUCt of ABBV-313. |
Up to Approximately Day 329
|
合作者和调查者
赞助
调查人员
- 研究主任:ABBVIE INC.、AbbVie
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.